← All trials
NCT03981822
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 27, 2019
- Primary completion
- Aug 12, 2020
- Completion date
- Oct 14, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 108
- Arms / groups
- 6 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Verrica Pharmaceuticals Inc.Lead sponsor
- BioClinica, Inc.Collaborator
- Instat servicesCollaborator
- Paidion Research, IncCollaborator
- Indiana Clinical Trials CenterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.